(Q38180166)

30 August 2017

A changing treatment landscape for multiple sclerosis: challenges and opportunities (English)

1 reference

30 August 2017

0 references

F Piehl

1

1 reference

PubMed ID

24444084

30 August 2017

language of work or name

English

0 references

publication date

17 March 2014

1 reference

Journal of Internal Medicine

30 August 2017

1 reference

30 August 2017

275

1 reference

30 August 2017

4

1 reference

30 August 2017

364-381

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

30 August 2017

1 reference

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Environmental factors and their timing in adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Evidence for a two-stage disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Progressive multiple sclerosis: pathology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Interferon-beta treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Effects of natalizumab treatment on Foxp3+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Fingolimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Fingolimod-associated macular edema: incidence, detection, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

B cells and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12204

21 January 2018

Identifiers

DOI

10.1111/JOIM.12204

1 reference

30 August 2017

1 reference

PubMed ID

24444084